Novo obesity drug could launch in U.S. end 2014

COPENHAGEN (Reuters) - Danish drug maker Novo Nordisk said it could launch obesity treatment liraglutide in the United States by the end of next year and rejected some analysts' doubts over the medicine's commercial potential.

Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/dytn1fj0li0/story01.htm

phlebotomy training in birmingham al phlebotomy certification in tennessee phlebotomy classes in chicago